The biological role of a gene variant implicated in multiple sclerosis (MS) has been determined by researchers at Oxford University. The finding explains why MS patients do badly on a set of drugs used successfully in other autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease - something that has been a puzzle for over 10 years.
